Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 259

Sort by

Sort Order Select

Journal Articles

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Blood (2023) 142 (19): 1647–1657.

https://doi.org/10.1182/blood.2023020649

Published: 2023

Includes: Supplemental data

Journal Articles

Influence of Co-Mutational Patterns in Disease Phenotype and Clinical Outcomes of Chronic Myelomonocytic Leukemia

Blood (2023) 142 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2023-178061

Published: 2023

Journal Articles

Single-Cell Polyfunctional Proteomic Profiling Reveals Temporal and Niche Differences in CD4 and CD8 T Cells in Acute Myeloid Leukemia Following PD-1 Blockade Therapy

Jessica Lynn Root, Poonam N Desai, Patrick K Reville, Christopher Ly, Bofei Wang, Fatima Z Jelloul, Jing Zhou, Sean Gregory Mackay, Mansour Alfayez, Jairo Matthews, Sherry Pierce, Naval Daver, Hussein A Abbas

Blood (2023) 142 (Supplement 1): 1584.

https://doi.org/10.1182/blood-2023-188268

Published: 2023

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1857.

https://doi.org/10.1182/blood-2023-189557

Published: 2023

Journal Articles

A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 833.

https://doi.org/10.1182/blood-2023-172658

Published: 2023

Journal Articles

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2023-182256

Published: 2023

Journal Articles

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)

Robert Briski, Nicholas J. Short, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo, Musa Yilmaz, Yesid Alvarado Valero, Kenneth Vaughan, Sherry Pierce, Kathryn Montalbano, Jillian Mullin, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi

Blood (2023) 142 (Supplement 1): 2910.

https://doi.org/10.1182/blood-2023-187429

Published: 2023

Journal Articles

Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML)

Blood (2023) 142 (Supplement 1): 870.

https://doi.org/10.1182/blood-2023-188236

Published: 2023

Journal Articles

Comprehensive Characterization of Evolution of Genomic Complexity By Structural Variant and Mutational Profiling in Myelodysplastic Syndrome Patients with Hypomethylating Agent Failure

Hui Yang, Guillermo Garcia-Manero, Kelly S. Chien, Koji Sasaki, Sherry Pierce, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna

Blood (2023) 142 (Supplement 1): 4612.

https://doi.org/10.1182/blood-2023-187719

Published: 2023

Journal Articles

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

Lucia Masarova, Hagop M. Kantarjian, Naveen Pemmaraju, Hussein A Abbas, Prithviraj Bose, Mahesh Swaminathan, Sherry Pierce, Koji Sasaki, Musa Yilmaz, Nicholas J. Short, Naval Daver, Gautam Borthakur, Guillermo Garcia-Manero, Maro Ohanian, Kapil N. Bhalla, Courtney D. DiNardo, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4264.

https://doi.org/10.1182/blood-2023-187968

Published: 2023

Journal Articles

Clinical and Prognostic Implications of WT1 Mutations in De Novo and Relapsed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 959.

https://doi.org/10.1182/blood-2023-188319

Published: 2023

Journal Articles

Deeper Insight into Splicing Mutations in Myelofibrosis

Julie Braish, Prithviraj Bose, Naveen Pemmaraju, Sherry Pierce, Koji Sasaki, Keyur P. Patel, Hagop Kantarjian, Lucia Masarova

Blood (2023) 142 (Supplement 1): 4580.

https://doi.org/10.1182/blood-2023-189168

Published: 2023

Journal Articles

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Mehrnoosh Tashakori, Tapan Kadia, Sanam Loghavi, Naval Daver, Rashmi Kanagal-Shamanna, Sherry Pierce, Dawen Sui, Peng Wei, Farnoosh Khodakarami, Zhenya Tang, Mark Routbort, Carol A. Bivins, Elias J. Jabbour, L. Jeffrey Medeiros, Kapil Bhalla, Hagop M. Kantarjian, Farhad Ravandi, Joseph D. Khoury

Blood (2022) 140 (1): 58–72.

https://doi.org/10.1182/blood.2021013983

Published: 2022

Includes: Supplemental data

Journal Articles

Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm

Naveen Pemmaraju, Nathaniel R. Wilson, Joseph D. Khoury, Nitin Jain, Naval Daver, Sherry Pierce, Elias Jabbour, Tapan Kadia, Courtney DiNardo, Guillermo Garcia-Manero, Muzaffar Qazilbash, Marina Konopleva, Hagop Kantarjian

Blood (2021) 138 (15): 1373–1377.

https://doi.org/10.1182/blood.2021011817

Published: 2021

Journal Articles

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

Naveen Pemmaraju, Hagop Kantarjian, Loretta Nastoupil, Megan Dupuis, Lisa Zhou, Sherry Pierce, Keyur P. Patel, Lucia Masarova, Jorge Cortes, Srdan Verstovsek

Blood (2019) 133 (21): 2348–2351.

https://doi.org/10.1182/blood-2019-01-897637

Published: 2019

Journal Articles

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

Blood (2018) 132 (16): 1664–1674.

https://doi.org/10.1182/blood-2018-04-846626

Published: 2018

Includes: Supplemental data

Journal Articles

The Clinical Benefit of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML): A Surrogate of Overall Survival (OS) or Meritorious on Its Own Right?

Abhishek Maiti, MBBS, Hagop M. Kantarjian, MD, Vinita Popat, BA†, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Srdan Verstovsek, MD PhD, Michael Andreeff, MD PhD, Gautam Borthakur, MD, Tapan Kadia, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Courtney D. DiNardo, MDMSc, Sherry Pierce, BSN, BA, William G Wierda, MD PhD, Steven Kornblau, MD, Farhad Ravandi, MBBS, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 4693.

https://doi.org/10.1182/blood.V130.Suppl_1.4693.4693

Published: 2017

Journal Articles

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 815.

https://doi.org/10.1182/blood.V130.Suppl_1.815.815

Published: 2017

Journal Articles

A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 2577.

https://doi.org/10.1182/blood.V130.Suppl_1.2577.2577

Published: 2017

Journal Articles

The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL)

Musa Yilmaz, MD, Devendra KC, MD, Mary Abisola Akosile, PhD, Joseph David Khoury, MD, Nicholas J Short, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Tapan Kadia, MD, Koji Sasaki, MD, Marina Konopleva, MD PhD, William G Wierda, MD PhD, Nitin Jain, MD, Srdan Verstovsek, MD PhD, Zeev Estrov, MD, Sherry Pierce, BSN, BA, Susan M. O'Brien, MD, Elias J. Jabbour, MD, Hagop M. Kantarjian, MD

Blood (2017) 130 (Supplement 1): 2712.

https://doi.org/10.1182/blood.V130.Suppl_1.2712.2712

Published: 2017

NARROW

Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Influence of Co-Mutational Patterns in Disease Phenotype and Clinical Outcomes of Chronic Myelomonocytic Leukemia

Single-Cell Polyfunctional Proteomic Profiling Reveals Temporal and Niche Differences in CD4 and CD8 T Cells in Acute Myeloid Leukemia Following PD-1 Blockade Therapy

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)

Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML)

Comprehensive Characterization of Evolution of Genomic Complexity By Structural Variant and Mutational Profiling in Myelodysplastic Syndrome Patients with Hypomethylating Agent Failure

Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs)

Clinical and Prognostic Implications of WT1 Mutations in De Novo and Relapsed Acute Myeloid Leukemia

Deeper Insight into Splicing Mutations in Myelofibrosis

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

The Clinical Benefit of Event-Free Survival (EFS) in Acute Myeloid Leukemia (AML): A Surrogate of Overall Survival (OS) or Meritorious on Its Own Right?

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia

The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only